Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA.

Schizophr Res. 2008 Aug;103(1-3):104-9. doi: 10.1016/j.schres.2008.04.023. Epub 2008 Jun 4.

2.

What CATIE found: results from the schizophrenia trial.

Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA.

Psychiatr Serv. 2008 May;59(5):500-6. doi: 10.1176/ps.2008.59.5.500.

3.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators..

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

4.

Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.

Ramsey TL, Brennan MD.

Schizophr Res. 2014 Dec;160(1-3):73-9. doi: 10.1016/j.schres.2014.09.038. Epub 2014 Oct 18.

5.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators..

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466
6.

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.

Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA.

World J Biol Psychiatry. 2009;10(4 Pt 3):710-8. doi: 10.1080/15622970802269589.

PMID:
18803070
7.

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.

Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M.

J Clin Psychiatry. 2009 Apr;70(4):487-99. Epub 2009 Apr 7.

8.

Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.

Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.

J Am Pharm Assoc (2003). 2007 May-Jun;47(3):373-8.

PMID:
17510032
9.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network..

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

10.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
11.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators.; Neurocognitive Working Group..

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
12.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators..

Am J Psychiatry. 2006 Apr;163(4):611-22.

PMID:
16585435
13.

Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.

Mohamed S, Rosenheck RA, Lin H, Swartz M, McEvoy J, Stroup S.

J Nerv Ment Dis. 2015 Jul;203(7):486-92. doi: 10.1097/NMD.0000000000000317.

PMID:
26075840
14.

Interpreting the results of the CATIE study.

Lieberman JA, Hsiao JK.

Psychiatr Serv. 2006 Jan;57(1):139. No abstract available.

PMID:
16399980
15.

Interpreting the results of the CATIE study.

Pandiani JA, Banks SM.

Psychiatr Serv. 2006 Jan;57(1):140-1. No abstract available.

PMID:
16399981
16.

Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Volavka J, Czobor P, Citrome L, Van Dorn RA.

CNS Spectr. 2014 Oct;19(5):374-81. doi: 10.1017/S1092852913000849. Epub 2013 Nov 28. Erratum in: CNS Spectr. 2014 Oct;19(5):466.

17.

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.

Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.

Schizophr Res. 2008 Jan;98(1-3):8-15. Epub 2007 Jun 26.

PMID:
17596914
18.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators..

Am J Psychiatry. 2006 Apr;163(4):600-10.

PMID:
16585434
19.

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.

JAMA. 2009 Oct 28;302(16):1765-73. doi: 10.1001/jama.2009.1549. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

20.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

Supplemental Content

Support Center